ClariVest Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

ClariVest Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-17,496	Closed	-$1.05M	–	778
2018 Q2	$1.05M	Sell	17,496 -906	-5%	-$46.9K	0.02%	436
2018 Q1	$843K	Buy	18,402 +100	+0.5%	+$4.17K	0.01%	449
2017 Q4	$730K	Sell	18,302 -1,196	-6%	-$47.3K	0.01%	454
2017 Q3	$780K	Buy	+19,498	New	+$844K	0.02%	354

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

ClariVest Asset Management's SUPN Position: Q3 2018 in Review

ClariVest Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2018, closing a stake of 17,496 shares — an estimated $1.05M sold.

ClariVest Asset Management first reported a position in SUPN in Q3 2017 and held it in 4 quarters. The position peaked at $1.05M in Q2 2018. 288 funds tracked by Wall St. Rank hold SUPN as of Q3 2018.

ClariVest Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
ClariVest Asset Management sold 17,496 Supernus Pharmaceuticals shares in Q3 2018, an estimated $1.05M.
ClariVest Asset Management first reported a position in Supernus Pharmaceuticals in Q3 2017 and held it in 4 quarters.
ClariVest Asset Management's Supernus Pharmaceuticals position peaked at $1.05M in Q2 2018.
288 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2018.

Based on ClariVest Asset Management's 13F filing for Q3 2018, filed 7 Nov 2018.